PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31138279-10 2019 Our hypothesis is that anesthesia with sevoflurane will result in a weaker proinflammatory response compared to anesthesia with propofol, with lower circulating levels of IL-6 and other proinflammatory mediators, and increased macrophage differentiation into the M2 phenotype in adipose tissue. Sevoflurane 39-50 interleukin 6 Homo sapiens 171-175 27020594-7 2016 IL-6 levels were significantly lower in the sevoflurane group than propofol group at 4 h and 1 d following FFB (61.3 +- 11.9 versus 82.6 +- 19.7 pg/ml; 52.8 +- 9.7 versus 75.4 +- 13.6 pg/ml, respectively). Sevoflurane 44-55 interleukin 6 Homo sapiens 0-4 30589029-3 2018 We hypothesized that DEX could reduce the incidence of POCD caused by sevoflurane anesthesia through decreasing plasma interleukin (IL-6) and tumor necrosis factor (TNF)-alpha concentrations. Sevoflurane 70-81 interleukin 6 Homo sapiens 132-136 30589029-10 2018 Conclusion: The POCD incidence was higher in elderly patients receiving sevoflurane anesthesia and DEX could alleviate POCD in these patients through decreasing plasma TNF-alpha and IL-6 concentrations. Sevoflurane 72-83 interleukin 6 Homo sapiens 182-186 29949172-7 2018 CONCLUSIONS: The prolonged sevoflurane inhalational anesthesia time (>= 3 h) enhanced the occurrence of POCD and was related to the expression levels of serum caspase-3, TNF-alpha, and IL-6. Sevoflurane 27-38 interleukin 6 Homo sapiens 188-192 28259141-5 2017 RESULTS: In the sevoflurane group, the plasma concentrations of cTnI and CK-MB from Tl to T4 and the levels of IL-6 and IL-10 from T1 to T2 were lower than those in the propofol group. Sevoflurane 16-27 interleukin 6 Homo sapiens 111-115 27020594-9 2016 CONCLUSIONS: In children with community-acquired pneumonia, use of sevoflurane was associated with lower circulating IL-6 and IL-10 levels compared with propofol, following FFB. Sevoflurane 67-78 interleukin 6 Homo sapiens 117-121 25626738-9 2015 Lower levels of MCP-1 and IL-8 (P < 0.001) and higher levels of IL-6 and MMP-9 (P = 0.003) were found in the sevoflurane group, compared with the TIVA group 30 min post-operatively. Sevoflurane 112-123 interleukin 6 Homo sapiens 67-71 25559834-8 2014 RESULTS: Interleukin 6 levels were significantly higher in propofol than in sevoflurane group (P=0.014). Sevoflurane 76-87 interleukin 6 Homo sapiens 9-22 23295714-8 2013 RESULTS: Sevoflurane suppressed TNF-alpha-induced IL-6, IL-8, and MCP-1 gene expression and the production of IL-6 and IL-8 in SAEC under anoxia/reoxygenation conditions. Sevoflurane 9-20 interleukin 6 Homo sapiens 50-54 23295714-8 2013 RESULTS: Sevoflurane suppressed TNF-alpha-induced IL-6, IL-8, and MCP-1 gene expression and the production of IL-6 and IL-8 in SAEC under anoxia/reoxygenation conditions. Sevoflurane 9-20 interleukin 6 Homo sapiens 110-114 23295714-12 2013 CONCLUSIONS: Sevoflurane suppressed the NF-kappaB-mediated production of pulmonary epithelial cell-derived inflammatory cytokines, including IL-6 and IL-8, which are capable of causing I/R injury. Sevoflurane 13-24 interleukin 6 Homo sapiens 141-145 22381051-9 2012 The level of IL-6 at the end of surgery was lower for sevoflurane (69.5 [35.9-121.0] pg/mL) than propofol-remifentanil (128.2 [92.8-163.8] pg/mL, p = 0.03), but this difference was not maintained 24 hours after surgery. Sevoflurane 54-65 interleukin 6 Homo sapiens 13-17 22381051-12 2012 CONCLUSIONS: Sevoflurane anesthesia attenuated an increase in blood IL-6 at the end of surgery but did not provide any advantages over propofol remifentanil in terms of postoperative pulmonary complications in Ivor Lewis operations. Sevoflurane 13-24 interleukin 6 Homo sapiens 68-72 21979104-10 2012 Moreover, IL-6 ELF level in the dependent lung was significantly higher in the propofol group than in the sevoflurane group after OLV (P < 0.001). Sevoflurane 106-117 interleukin 6 Homo sapiens 10-14 15232804-14 2004 IL-6 levels (pg/mL) were found to be lower in the sevoflurane group compared with controls at T2 arterial circulation (38.2 +/- 21.1 v 60.6 +/- 19.1, p < 0.05) as well as in the coronary circulation (38.4 +/- 19.9 v 118.2 +/- 23.5, p < 0.01) at T2. Sevoflurane 50-61 interleukin 6 Homo sapiens 0-4 15232804-19 2004 CONCLUSIONS: Sevoflurane decreases the inflammatory response after CPB, as measured by the release of IL-6, CD11b/CD18, and TNF-alpha. Sevoflurane 13-24 interleukin 6 Homo sapiens 102-106 11594792-3 2001 Plasma IL-6 concentrations (92.3+/- 31.9 pg/ml) in elderly patients anesthetized with propofol and fentanyl were significantly higher at the end of the operation than that (57.9+/-36.7 pg/ml) of elderly patients anesthetized with sevoflurane and fentanyl. Sevoflurane 230-241 interleukin 6 Homo sapiens 7-11 11594792-5 2001 Plasma IL-6 production after surgical trauma in elderly patients with total intravenous anesthesia with propofol was significantly higher than that in elderly patients with sevoflurane anesthesia. Sevoflurane 173-184 interleukin 6 Homo sapiens 7-11 26782552-0 2015 Sevoflurane downregulates interleukin-6 and interleukin-8 levels in patients after cardiopulmonary bypass surgery: a meta-analysis. Sevoflurane 0-11 interleukin 6 Homo sapiens 26-39 26782552-1 2015 This study aimed to investigate the effect of sevoflurane on serum levels of interleukin (IL)-6 and IL-8 in patients who underwent cardiopulmonary bypass (CPB). Sevoflurane 46-57 interleukin 6 Homo sapiens 77-95 26782552-2 2015 The strength of the association between sevoflurane treatment and serum level of IL-6 and IL-8 was determined in patients who underwent CPB by summary standard mean differences (SMDs); 95% confidence interval (CI) was used. Sevoflurane 40-51 interleukin 6 Homo sapiens 81-85 26782552-3 2015 In total, seven case-control studies showed decreased IL-6 and IL-8 levels in sevoflurane-treated patients than in controls (IL-6: SMD = 1.56, 95%CI: 0.95-2.17, P < 0.001; IL-8: SMD = 1.63, 95%CI: 0.30-2.96, P < 0.001, respectively). Sevoflurane 78-89 interleukin 6 Homo sapiens 54-58 26782552-3 2015 In total, seven case-control studies showed decreased IL-6 and IL-8 levels in sevoflurane-treated patients than in controls (IL-6: SMD = 1.56, 95%CI: 0.95-2.17, P < 0.001; IL-8: SMD = 1.63, 95%CI: 0.30-2.96, P < 0.001, respectively). Sevoflurane 78-89 interleukin 6 Homo sapiens 125-129 26782552-4 2015 Further, IL-6 and IL-8 levels were significantly higher in sevoflurane-treated patients than in sevoflurane-pretreated patients (IL-6 post vs pre: SMD = 2.17, 95%CI: 1.40-2.95, P < 0.001; IL-8 post vs pre: SMD = 4.01, 95%CI: 2.80-5.21, P < 0.001, respectively). Sevoflurane 59-70 interleukin 6 Homo sapiens 9-13 26782552-4 2015 Further, IL-6 and IL-8 levels were significantly higher in sevoflurane-treated patients than in sevoflurane-pretreated patients (IL-6 post vs pre: SMD = 2.17, 95%CI: 1.40-2.95, P < 0.001; IL-8 post vs pre: SMD = 4.01, 95%CI: 2.80-5.21, P < 0.001, respectively). Sevoflurane 59-70 interleukin 6 Homo sapiens 129-133 26782552-4 2015 Further, IL-6 and IL-8 levels were significantly higher in sevoflurane-treated patients than in sevoflurane-pretreated patients (IL-6 post vs pre: SMD = 2.17, 95%CI: 1.40-2.95, P < 0.001; IL-8 post vs pre: SMD = 4.01, 95%CI: 2.80-5.21, P < 0.001, respectively). Sevoflurane 96-107 interleukin 6 Homo sapiens 129-133 26782552-5 2015 CPB-stratified analysis showed significant decrease in IL-6 and IL-8 levels in sevoflurane-treated patients than in controls, irrespective of the time after CPB surgery (P < 0.05). Sevoflurane 79-90 interleukin 6 Homo sapiens 55-59 26782552-6 2015 Moreover, sevoflurane-pretreated patients under the <12-h subgroup showed decreased IL-6 levels (P = 0.698), while all other subgroups showed decreased IL-8 levels (P < 0.05). Sevoflurane 10-21 interleukin 6 Homo sapiens 87-91 26782552-7 2015 Further, subgroup analysis by different dose of sevoflurane showed decreased IL-6 and IL-8 levels in subgroups administered with a dose of <2 and >= 2% sevoflurane under the case vs control and pre- vs post-treatment of sevoflurane models. Sevoflurane 48-59 interleukin 6 Homo sapiens 77-81 26782552-7 2015 Further, subgroup analysis by different dose of sevoflurane showed decreased IL-6 and IL-8 levels in subgroups administered with a dose of <2 and >= 2% sevoflurane under the case vs control and pre- vs post-treatment of sevoflurane models. Sevoflurane 158-169 interleukin 6 Homo sapiens 77-81 26782552-7 2015 Further, subgroup analysis by different dose of sevoflurane showed decreased IL-6 and IL-8 levels in subgroups administered with a dose of <2 and >= 2% sevoflurane under the case vs control and pre- vs post-treatment of sevoflurane models. Sevoflurane 158-169 interleukin 6 Homo sapiens 77-81 26782552-8 2015 Serum IL-6 and IL-8 levels were significantly lower in sevoflurane-treated patients who underwent CPB, suggesting sevoflurane pretreatment to be more beneficial than post-treatment. Sevoflurane 55-66 interleukin 6 Homo sapiens 6-10 26782552-8 2015 Serum IL-6 and IL-8 levels were significantly lower in sevoflurane-treated patients who underwent CPB, suggesting sevoflurane pretreatment to be more beneficial than post-treatment. Sevoflurane 114-125 interleukin 6 Homo sapiens 6-10 26497059-11 2015 Furthermore, we found elevated plasma concentrations of S-100beta protein, TNF-alpha and IL-6 in those receiving sevoflurane anesthesia. Sevoflurane 113-124 interleukin 6 Homo sapiens 89-93 24788377-8 2014 The results indicated that the levels of IL-6 in ELF were significantly increased in both the ventilated DL and collapsed NDL after OLV compared with the levels prior to OLV in the sevoflurane group. Sevoflurane 181-192 interleukin 6 Homo sapiens 41-45 23552565-9 2013 Both 3 and 7% sevoflurane decreased TNF-alpha and IL-6 levels at 24 hours (both p<0.05). Sevoflurane 14-25 interleukin 6 Homo sapiens 50-54 23552565-11 2013 Both 3% and 7% sevoflurane decreased TNF-alpha and IL-6 levels at 24 hours (both p<0.05). Sevoflurane 15-26 interleukin 6 Homo sapiens 51-55 23552565-12 2013 CONCLUSIONS: Postconditioning with the halogenated anesthetic agent sevoflurane after LPS stimulation shows a cytoprotective effect in an in vitro model, decreasing cell death and reducing TLR2 and TLR4 expression as well as levels of the inflammatory mediators TNF-alpha and IL-6 in human endothelial cells. Sevoflurane 68-79 interleukin 6 Homo sapiens 276-280 16884979-14 2006 CONCLUSION: Sevoflurane suppressed the production of IL-6 and IL-8, but not IL-10 and IL-1ra. Sevoflurane 12-23 interleukin 6 Homo sapiens 53-57 34277696-11 2021 Compared with the propofol group, BAL levels of IL-6 in the dependent ventilated lung were decreased in the sevoflurane group (three trials, 256 participants; standardized mean difference (SMD), -0.51; 95% confidence interval (CI), -0.90 to -0.11; p = 0.01; I 2 = 46%). Sevoflurane 108-119 interleukin 6 Homo sapiens 48-52 34277696-12 2021 The BAL levels of IL-6 in the independent ventilated lung were also decreased by sevoflurane (four trials, 362 participants; SMD, -0.70; 95% (CI), -0.93 to -0.47; p < 0.00001; I 2 = 0%). Sevoflurane 81-92 interleukin 6 Homo sapiens 18-22 33145215-12 2020 The level of IL-6 decreased significantly at the end of surgery compared to baseline in patients receiving sevoflurane (P = 0.040). Sevoflurane 107-118 interleukin 6 Homo sapiens 13-17 33145215-15 2020 The decrease in IL-6 level reflects anti-inflammatory effect and probable neuroprotective potential of propofol and sevoflurane. Sevoflurane 116-127 interleukin 6 Homo sapiens 16-20